The Role of Non-Statin Therapies for LDL-C Lowering for Management of ASCVD Risk

Released On
September 28, 2018

Expires On
September 28, 2019

Media Type
Internet

Completion Time
60 minutes

Specialty
Cardiology, Primary Care

Topic(s)
LDL-C Management

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians’ Education Resource®, LLC.

 

Supported by an educational grant from Amgen.

 

Credit Available

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)
  • Nurses — 1.0 contact hours.

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This continuing medical education (CME) activity is primarily intended for family physicians who treat patients with cardiovascular risk factors including hypercholesterolemia.

Statement of Need/Program Overview

Statins have been the mainstream of hypercholesterolemia treatment for over 30 years, but clinicians now have effective nonstatin options when lipid-lowering goals are not met or when patients become statin intolerant. Besides bile acid binding resins and a cholesterol absorption inhibitor, 2 proprotein convertase subtilisin kexin type 9 (PCSK9) inhibitors have been available since 2015, alirocumab and evolocumab to provide a more aggressive approach to lipid-lowering.

In this Community Practice Connections™, 2 leading family-practice physicians will provide insight on statin intolerance and discuss nonstatin treatment options as well as compare and contrast indications for the PCSK9 inhibitors. Key points to incorporate PCSK9 inhibitors into clinical practice and tips to facilitate patient access will be included to readily broaden clinicians’ armamentarium of lipid-lowering treatments.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize the latest guidelines and recommendations on cholesterol management from major clinical organizations
  • Review potential cholesterol-lowering therapies beyond statins, and explain when these non-statin therapies should be considered
  • State the indications in detail for proprotein convertase subtilisin kexin type 9 inhibitor (PCSK9i) therapy

Faculty

Stephen A. Brunton, MD

Adjunct Clinical Professor
Department of Pharmacy Practice
Roseman University of Health Sciences
Salt Lake City, Utah

Michael Cobble, MD, FNLA

Director
Canyons Medical Center
Sandy, Utah

Adjunct Faculty
The University of Utah
Salt Lake City, Utah

Accreditation/Credit Designation Statement

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians and is a provider approved by the California Board of Registered Nursing (CBRN).

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™ and for 1.0 contact hours for nurses. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

All other health care professionals completing this course will be issued a statement of participation.

Disclosures of Conflicts of Interest

The following contributors have relevant financial relationships with commercial interests to disclose:

Michael Cobble, MD, FNLA

  • Consultant: Kowa Pharmaceuticals America, Inc
  • Speakers Bureau: Amarin Corporation, Amgen, AstraZeneca, Kowa Pharmaceuticals America, Inc, Sanofi

Stephen A. Brunton has no relevant financial relationships with commercial interests to disclose.

Method of Participation

There are no fees to participate in the activity. Participants must review all activity information, including the learning objectives, disclosure statements, and content. To receive credit for participation, participants must complete the post-test (achieving a passing grade) and program evaluation. Certificates can be printed immediately.

Course Viewing Requirements

Supported Browsers:
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above

Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above.

Disclaimer/Disclosure of Unlabeled Use

This activity may or may not discuss investigational, unapproved, or off-label uses of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to the diagnostic, treatment, and management options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of Physicians’ Education Resource®, LLC, or any of the companies that provided commercial support for this activity.